Inferra AI / Company / CRVS
Corvus Pharmaceuticals, Inc.
CRVS · Health Care
Last earnings Aug 6, 2026
AI analysis
Q2 2028 · reported Aug 6, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
“of $8.1 million”
Guidance stated in the release for the second quarter of 2028; figures as stated.
Capital allocation
The Company intends to raise additional capital through private and public equity offerings, debt financings and license and development agreements.
The exercise price and the number of shares of common stock issuable upon exercise of the pre-funded warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock.
Event summary
(Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
research and development expenses: “research and development expenses of $8.1 million”
research and development expenses (“the second quarter of 2028”)
“The increase in research and development expenses of $8.1 million was primarily due to higher clinical trial costs associated with the development of soquelitinib as well as an increase in personnel related costs.”
Guidance stated in the release for the second quarter of 2028; figures as stated.
Capital allocation
The Company intends to raise additional capital through private and public equity offerings, debt financings and license and development agreements.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The exercise price and the number of shares of common stock issuable upon exercise of the pre-funded warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The exercise price and the number of shares of common stock (or pre-funded warrants in lieu thereof) issuable upon exercise of the common warrants were subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the 16 Table of Contents common stock.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Common stockholders are entitled to dividends if and when declared by the board of directors.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
As of June 30, 2026, no dividends on common stock had been declared.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
As the interest rate implicit in lease arrangements is typically not readily available, in calculating the present value of the lease payments, the Company has utilized its incremental borrowing rate, which is determined based on the prevailing market rates for collateralized debt with maturity dates commensurate with the term of its lease.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
We are focused on driving enrollment in our registrational Phase 3 relapsed/refractory PTCL and Phase 2 atopic dermatitis trials, and we are working closely with our partner in China, Angel Pharmaceuticals, on their Phase 1b/2 atopic dermatitis trial.
SEC original ↗Corvus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Business Update and Strategy Soquelitinib for Immune Diseases Final data from the randomized, blinded, placebo-controlled Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis were presented in two oral sessions at the Society for Investigative Dermatology (SID) Annual Meeting.
SEC original ↗Corvus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Forward-Looking Statements This press release contains forward-looking statements, including statements related to the potential safety, tolerability, clinical benefit and efficacy of the Company s product candidates; the potential use of soquelitinib to improve therapy for a broad range of patients with atopic dermatitis, other immune diseases and cancers; clinical strategy and the design of clinical trials, including the Company s collaborations and the timeline for initiation, target or expected number of patients to be enrolled, dose levels, number of sites and other product development milestones; market size; and the amount of cash to fund operations into the second quarter of 2028.
SEC original ↗Corvus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Since commencing operations in 2014, the majority of the Company s efforts have been focused on the research and development of soquelitinib, ciforadenant and mupadolimab.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company s control.
SEC original ↗Corvus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026
Legal Proceedings 41 Item 1A.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Liquidity The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Failure to manage discretionary spending or raise additional capital, as needed, may adversely impact the Company s ability to achieve its intended business objectives.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Concentrations of Credit Risk and Other Risks and Uncertainties Substantially all of the Company s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event.
SEC original ↗Corvus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
36 documents- Q2 2026
- 10-QCRVS
- 8-KCRVS
- EX-99CRVS
- 8-KCRVS
- Q1 2026
- 8-KCRVS
- 8-KCRVS
- 10-QCRVS
- 8-KCRVS
- 8-KCRVS
- Q4 2025
- 8-KCRVS
- 10-KCRVS
- 8-KCRVS
- 8-KCRVS
- 8-KCRVS
- 8-KCRVS
- EX-99CRVS
- Q3 2025
- 10-QCRVS
- 8-KCRVS
- 8-KCRVS
- Q2 2025
- 8-KCRVS
- 10-QCRVS
- Q1 2025
- 8-KCRVS
- 8-KCRVS
- EX-99CRVS
- 8-KCRVS
- 10-QCRVS
- EX-99CRVS
- 8-KCRVS
- Q4 2024
- 8-KCRVS
- 10-KCRVS
- 8-KCRVS
- EX-99CRVS
- Q3 2024
- 8-KCRVS
- EX-99CRVS
- 8-KCRVS
- 10-QCRVS
Earnings releases
8 documentsPresentations
0 documentsNo presentations for Corvus Pharmaceuticals, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Corvus Pharmaceuticals, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.